79 related articles for article (PubMed ID: 28554844)
1. Control of cancer stem cell like population by intracellular target identification followed by the treatment with peptide-siRNA complex.
Suh JS; Lee HJ; Nam H; Jo BS; Lee DW; Kim JH; Lee JY; Chung CP; Lee G; Park YJ
Biochem Biophys Res Commun; 2017 Sep; 491(3):827-833. PubMed ID: 28554844
[TBL] [Abstract][Full Text] [Related]
2. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine.
Choi YS; Lee JY; Suh JS; Kwon YM; Lee SJ; Chung JK; Lee DS; Yang VC; Chung CP; Park YJ
Biomaterials; 2010 Feb; 31(6):1429-43. PubMed ID: 19954842
[TBL] [Abstract][Full Text] [Related]
3. Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF-κB/microRNA 448 circuit.
Mak KK; Wu AT; Lee WH; Chang TC; Chiou JF; Wang LS; Wu CH; Huang CY; Shieh YS; Chao TY; Ho CT; Yen GC; Yeh CT
Mol Nutr Food Res; 2013 Jul; 57(7):1123-34. PubMed ID: 23504987
[TBL] [Abstract][Full Text] [Related]
4. Targeting choline phospholipid metabolism: GDPD5 and GDPD6 silencing decrease breast cancer cell proliferation, migration, and invasion.
Cao MD; Cheng M; Rizwan A; Jiang L; Krishnamachary B; Bhujwalla ZM; Bathen TF; Glunde K
NMR Biomed; 2016 Aug; 29(8):1098-107. PubMed ID: 27356959
[TBL] [Abstract][Full Text] [Related]
5. The effects of CD44 down-regulation on stem cell properties of head and neck cancer cell lines.
Kidwai F; Costea DE; Hutchison I; Mackenzie I
J Oral Pathol Med; 2013 Oct; 42(9):682-90. PubMed ID: 23627635
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis reveals that CD147/EMMPRIN confers chemoresistance in cancer stem cell-like cells.
Kang MJ; Kim HP; Lee KS; Yoo YD; Kwon YT; Kim KM; Kim TY; Yi EC
Proteomics; 2013 May; 13(10-11):1714-25. PubMed ID: 23554123
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells.
Park SY; Kim MJ; Park SA; Kim JS; Min KN; Kim DK; Lim W; Nam JS; Sheen YY
Oncotarget; 2015 Nov; 6(35):37526-43. PubMed ID: 26462028
[TBL] [Abstract][Full Text] [Related]
8. Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047.
Cirenajwis H; Smiljanic S; Honeth G; Hegardt C; Marton LJ; Oredsson SM
Anticancer Drugs; 2010 Nov; 21(10):897-906. PubMed ID: 20838207
[TBL] [Abstract][Full Text] [Related]
9. Silencing stem cell factor attenuates stemness and inhibits migration of cancer stem cells derived from Lewis lung carcinoma cells.
Wang L; Wang J; Li Z; Liu Y; Jiang M; Li Y; Cao D; Zhao M; Wang F; Luo F
Tumour Biol; 2016 Jun; 37(6):7213-27. PubMed ID: 26666817
[TBL] [Abstract][Full Text] [Related]
10. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth.
Zoubeidi A; Rocha J; Zouanat FZ; Hamel L; Scarlata E; Aprikian AG; Chevalier S
Mol Cancer Res; 2009 Jan; 7(1):142-55. PubMed ID: 19147545
[TBL] [Abstract][Full Text] [Related]
11. Carbon ion beam combined with cisplatin effectively disrupts triple negative breast cancer stem-like cells in vitro.
Sai S; Vares G; Kim EH; Karasawa K; Wang B; Nenoi M; Horimoto Y; Hayashi M
Mol Cancer; 2015 Sep; 14():166. PubMed ID: 26338199
[TBL] [Abstract][Full Text] [Related]
12. ZEB1 knockdown mediated using polypeptide cationic micelles inhibits metastasis and effects sensitization to a chemotherapeutic drug for cancer therapy.
Fang S; Wu L; Li M; Yi H; Gao G; Sheng Z; Gong P; Ma Y; Cai L
Nanoscale; 2014 Sep; 6(17):10084-94. PubMed ID: 25032749
[TBL] [Abstract][Full Text] [Related]
13. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate.
Govindarajan S; Sivakumar J; Garimidi P; Rangaraj N; Kumar JM; Rao NM; Gopal V
Biomaterials; 2012 Mar; 33(8):2570-82. PubMed ID: 22192536
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer.
Chu PY; Hu FW; Yu CC; Tsai LL; Yu CH; Wu BC; Chen YW; Huang PI; Lo WL
Oral Oncol; 2013 Jan; 49(1):34-41. PubMed ID: 22892238
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the transcription factor Sp1 suppresses colon cancer stem cell growth and induces apoptosis in vitro and in nude mouse xenografts.
Zhao Y; Zhang W; Guo Z; Ma F; Wu Y; Bai Y; Gong W; Chen Y; Cheng T; Zhi F; Zhang Y; Wang J; Jiang B
Oncol Rep; 2013 Oct; 30(4):1782-92. PubMed ID: 23877322
[TBL] [Abstract][Full Text] [Related]
16. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of SDF-1 activates the NF-κB pathway to induce epithelial to mesenchymal transition and cancer stem cell-like phenotypes of breast cancer cells.
Kong L; Guo S; Liu C; Zhao Y; Feng C; Liu Y; Wang T; Li C
Int J Oncol; 2016 Mar; 48(3):1085-94. PubMed ID: 26782945
[TBL] [Abstract][Full Text] [Related]
18. CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery.
Egorova A; Shubina A; Sokolov D; Selkov S; Baranov V; Kiselev A
Int J Pharm; 2016 Dec; 515(1-2):431-440. PubMed ID: 27789364
[TBL] [Abstract][Full Text] [Related]
19. The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation.
Buijs JT; van der Horst G; van den Hoogen C; Cheung H; de Rooij B; Kroon J; Petersen M; van Overveld PG; Pelger RC; van der Pluijm G
Oncogene; 2012 Apr; 31(17):2164-74. PubMed ID: 21996751
[TBL] [Abstract][Full Text] [Related]
20. Grp78 as a therapeutic target for refractory head-neck cancer with CD24(-)CD44(+) stemness phenotype.
Chiu CC; Lee LY; Li YC; Chen YJ; Lu YC; Li YL; Wang HM; Chang JT; Cheng AJ
Cancer Gene Ther; 2013 Nov; 20(11):606-15. PubMed ID: 24201869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
